PRO-DEX, INC. — Form 10-Q Summary
Reporting period: The filing covers the three and nine months ended March 31, 2022, Pro-Dex’s fiscal 2022 third quarter. The request metadata says “2021 Q3,” which does not match the filing period. Financial amounts below are in millions of dollars unless otherwise noted; statements are unaudited.
Business context and results
Pro-Dex designs and manufactures surgical drivers and shavers, principally for orthopedic, cranio-maxillofacial and thoracic markets, and also sells rotary air motors. Medical-device products accounted for 70% of quarterly sales and 79% of nine-month sales.
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Net sales, 2022 / 2021 | $9.265 / $11.739 (-21%) | $29.426 / $28.594 (+3%) |
| Gross profit, 2022 / 2021 | $2.858 / $4.385 | $9.689 / $10.456 |
| Gross margin, 2022 / 2021 | 31% / 37% | 33% / 37% |
| Operating income, 2022 / 2021 | $1.021 / $1.865 | $3.940 / $3.935 |
| Net income, 2022 / 2021 | $0.462 / $2.131 | $2.450 / $5.039 |
| Diluted EPS, 2022 / 2021 | $0.12 / $0.54 | $0.65 / $1.26 |
Quarterly sales weakness reflected lower medical-device shipments, including a delay associated with the largest customer’s next-generation device and lower thoracic shipments as a customer filled near-term distribution needs. Nine-month medical-device sales declined 2%, while total sales increased due to higher repairs and other revenue. Two customers represented 80% of sales in both the quarter and nine-month period; the largest alone represented 64% of nine-month sales.
Cash flow, liquidity and debt
- Nine-month operating cash flow was $4.432 million, versus cash use of $2.803 million in the prior-year period. The current period included a $3.429 million inventory increase, primarily to replenish subassemblies and long-lead-time parts.
- Investing cash use was $1.636 million, mainly for $1.270 million of equipment and building improvements. Financing cash use was $1.756 million, including $1.255 million of share repurchases and $0.561 million of principal payments.
- At March 31, cash and cash equivalents were $4.761 million; working capital was $20.376 million. Current assets were $28.099 million and current liabilities $7.723 million.
- The balance sheet reports notes payable of $12.217 million, including current and non-current portions, and lease liabilities of $2.521 million. The company’s detailed loan note lists outstanding property and term-loan balances that do not appear to reconcile exactly to the balance-sheet notes-payable total; investors may wish to verify the difference. The $2.0 million revolving facility was undrawn.
- Management said existing cash, receivables and expected operating cash flows should meet requirements for at least 12 months. It also noted possible use of investments or borrowing, and that additional debt or equity could be needed to support working capital and capital equipment.
Changes, outlook and notable items
- Quarterly gross margin fell six percentage points year over year. Management attributed the decline to lower sales and fixed-cost under-absorption, as well as inventory and warranty charges, including higher-priced components and write-downs. Supplier surcharges and price protections in customer contracts limited the ability to pass on cost increases.
- Management said supply-chain delays and longer lead times persisted and worsened in early 2022. Alternative sourcing of replacement chips helped mitigate the third-quarter impact, but at higher prices. It expected the disruption to affect results in the short term, potentially including the fourth quarter, while stating its long-term prospects remained positive.
- Backlog was approximately $21.2 million at March 31; $7.9 million was scheduled for delivery in fiscal Q4 and the remainder in the next fiscal year. Backlog is firm acknowledged orders and does not include all expected revenue under existing contracts.
- Management’s development plans include an ENT shaver, with a projected Q4 fiscal 2022 launch and estimated annual revenue of $1.0 million, and a ventilator, with a projected Q1 fiscal 2023 launch and estimated annual revenue of $1.5 million. These are estimates, not guaranteed outcomes; the filing warns products may be delayed, abandoned or generate less revenue than estimated.
- Investment portfolio volatility materially affected comparisons: the current nine-month period recorded $0.427 million of unrealized losses, versus $1.442 million of unrealized gains and $0.795 million of gains on investment sales in the prior-year period. Prior-year comparative statements were revised for an immaterial prior-period accounting error involving equity-investment fair-value changes; the revision increased reported prior-year net income.
- A customer sought indemnification in connection with a third-party patent-infringement claim involving a product Pro-Dex manufactures. The company disputes infringement and patent validity, intends to defend the matter, expects resolution may take two years or more, and has not accrued a liability. A former-employee matter was settled in February 2022.
- The company repurchased 52,718 shares for $1.255 million during the nine months. Disclosure controls were assessed as effective as of March 31, 2022; the filing reported no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the intended reporting period: the filing is for fiscal Q3 2022, not Q3 2021.
- Assess the durability of customer demand and the concentration risk, particularly the largest customer’s 64% share of nine-month sales.
- Track supplier availability, component pricing, backlog conversion and whether fourth-quarter shipments met the schedule disclosed.
- Reconcile the balance-sheet notes-payable amount with the individual loan balances in the debt note, and monitor covenants, maturities and balloon payments.
- Evaluate the valuation and liquidity of the marketable equity portfolio, including thinly traded holdings and related-party connections disclosed for Air T, Inc.
- Monitor the patent-indemnification claim, warranty accruals and whether planned product launches and revenue estimates are achieved.